Pharma BD Deal Intelligence
Sanofi's up-to-$1.2B AI discovery bet with Insilico Medicine delivered exactly one disclosed hit: an undruggable oncology transcription factor target found via Chemistry42, which Insilico then took back in-house after Sanofi's own reprioritization — a thin return on six nominated targets and just $21.5M upfront.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi will pay Insilico Medicine up to 1.2 billion dollars in milestones plus 21.5 million upfront for AI-discovered drug candidates against up to six…
Insilico Medicine signs strategic research collaboration with Sanofi worth up to $1.2 billion; $21.5M upfront and target-nomination fees, up to six targets via…
Oct 30, 2024: Insilico achieves milestone in Sanofi collaboration - AI lead with first-in-class potential vs an undruggable transcription factor in oncology;…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi entered a multi-year strategic research collaboration with Insilico Medicine (announced November 8, 2022) to deploy Insilico's end-to-end Pharma.AI platform to advance drug candidates against up to six novel targets. Insilico received $21.5M in upfront and target-nomination fees and is eligible for up to $1.2B in research, development and sales milestones plus royalties. On October 30, 2024, Insilico announced the collaboration's first disclosed milestone: an AI-facilitated lead with first-in-class potential against a previously "undruggable" transcription factor target in oncology, generated using Insilico's Chemistry42 engine. Insilico elected to bring that program in-house following a reprioritization by Sanofi, while the companies continue to collaborate on other targets using Insilico's AI discovery tools.
$2.9B Global AI drug discovery market 2022 · ~$1.22B Total deal BD value (up to, incl. milestones + royalties)
The Sanofi-Insilico Medicine collaboration spans up to six undisclosed targets discovered using Insilico's Pharma.AI generative AI platform, with no specific indication disclosed at signing — though Insilico's broader pipeline emphasizes oncology (TNK1, USP1, KAT6), fibrosis (idiopathic pulmonary fibrosis, lead asset INS018_055/rentosertib), and immunology (Q-fever-associated AhR, COVID-19). The deal is one of the most economically substantial AI drug discovery alliances signed to date — Sanofi paid $21.5M upfront with $1.2B+ in milestones representing a roughly 6:1 milestone-to-upfront ratio that exceeds prior AI platform precedents (Exscientia, BenevolentAI, Recursion, Atomwise). The strategic premise is that generative AI can compress hit-to-IND timelines from a typical 4-6 years to 18-30 months while improving target-druggability prediction accuracy. Insilico's most-validated commercial proof point is INS018_055, an oral TNIK inhibitor for IPF that entered Phase 2 in May 2023 — the first AI-discovered, AI-target-validated drug to advance from generative AI to Phase 2 anywhere in the industry. Pharma's AI investment thesis remains unproven on commercial endpoints (no AI-discovered approved drug as of 2022), making partnership economics rather than royalty streams the near-term value driver.
The AI drug discovery competitive landscape is bifurcated between platform companies and AI-augmented pharma in-house functions. Validated platform partners include Exscientia (Sanofi prior partner via 2022 deal also worth up to $5.2B; Bristol Myers prior $1.2B; Sumitomo asset DSP-1181 first AI-designed clinical compound, discontinued 2022), BenevolentAI (AstraZeneca chronic kidney disease, idiopathic pulmonary fibrosis), Recursion (Roche/Genentech $300M up to $12B), Schrodinger (BMS $55M up to $2.7B), Atomwise (multiple), and Isomorphic Labs (Eli Lilly $1.7B and Novartis $1.2B in 2024). Insilico differentiates on the basis of integrated platform spanning target identification (PandaOmics), small molecule design (Chemistry42), and clinical trial design (InClinico) — versus single-stage competitors. INS018_055 (rentosertib) Phase 2 IPF readout is the most-watched AI drug discovery clinical milestone of the 2025-2026 timeframe and will materially shape pharma BD valuations across the modality.
Insilico announced the collaboration's first disclosed milestone: an AI-facilitated lead with first-in-class potential against a previously undruggable transcription factor in oncology. Insilico elected to bring the program in-house following a reprioritization by Sanofi; the companies continue collaborating on other targets.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Insilico Medicine Inc. (this deal) | 2022 | $1.2B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2022 deals · Sanofi SA deals · Multiple (undisclosed) deals